MILAN, Italy--(BUSINESS WIRE)--Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global company and a leader in the treatment of cardiovascular diseases, announced today that it has completed the divestiture of its Renal Care Business to an investment consortium led by Argos Soditic, an independent European private equity firm, and MPS Venture SGR, on behalf of the closed-end fund ‘Emilia Venture’. The new owners have purchased the entire Sorin renal care business worldwide, under the brands Bellco and Laboratoire Soludia, recognised leaders in innovative therapies for the treatment of acute and chronic dialysis patients.
